4.87
price up icon3.62%   0.17
after-market Dopo l'orario di chiusura: 4.87
loading
Precedente Chiudi:
$4.70
Aprire:
$4.67
Volume 24 ore:
140.65K
Relative Volume:
1.15
Capitalizzazione di mercato:
$255.30M
Reddito:
$34.16M
Utile/perdita netta:
$-98.43M
Rapporto P/E:
-2.0812
EPS:
-2.34
Flusso di cassa netto:
$-119.33M
1 W Prestazione:
+0.00%
1M Prestazione:
+19.36%
6M Prestazione:
+3.18%
1 anno Prestazione:
-16.61%
Intervallo 1D:
Value
$4.67
$5.19
Intervallo di 1 settimana:
Value
$4.62
$5.19
Portata 52W:
Value
$2.9448
$10.25

Foghorn Therapeutics Inc Stock (FHTX) Company Profile

Name
Nome
Foghorn Therapeutics Inc
Name
Telefono
617-586-3100
Name
Indirizzo
500 TECHNOLOGY SQUARE, CAMBRIDGE
Name
Dipendente
112
Name
Cinguettio
Name
Prossima data di guadagno
2025-03-07
Name
Ultimi documenti SEC
Name
FHTX's Discussions on Twitter

Confronta FHTX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
FHTX
Foghorn Therapeutics Inc
4.87 255.30M 34.16M -98.43M -119.33M -2.34
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
452.16 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
534.91 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.06 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
542.47 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.16 28.51B 3.81B -644.79M -669.77M -6.24

Foghorn Therapeutics Inc Stock (FHTX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-04-23 Iniziato Citizens JMP Mkt Outperform
2025-01-30 Iniziato B. Riley Securities Buy
2024-09-03 Iniziato Jefferies Buy
2024-08-19 Iniziato Evercore ISI Outperform
2023-03-28 Iniziato BofA Securities Buy
2023-01-05 Iniziato BMO Capital Markets Outperform
2021-11-22 Iniziato H.C. Wainwright Buy
2020-11-17 Iniziato Cowen Outperform
2020-11-17 Iniziato Goldman Buy
2020-11-17 Iniziato Morgan Stanley Overweight
2020-11-17 Iniziato Wedbush Outperform
Mostra tutto

Foghorn Therapeutics Inc Borsa (FHTX) Ultime notizie

pulisher
Jun 17, 2025

Foghorn Therapeutics Holds Successful Annual Meeting - TipRanks

Jun 17, 2025
pulisher
Jun 17, 2025

Bank of America Corp DE Has $149,000 Stock Position in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World

Jun 17, 2025
pulisher
Jun 13, 2025

Soft Tissue Sarcoma Pipeline 2025: MOA, ROA, FDA-Approved Drugs, And Clinical Trial Progress Assessment By Delveinsight Oncotherapy Science, Foghorn Therapeutics, C4 Therapeutics, Lyvgen Biopharma - MENAFN.com

Jun 13, 2025
pulisher
Jun 11, 2025

Soft Tissue Sarcoma Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | OncoTherapy Science, Foghorn Therapeutics, C4 Therapeutics, Lyvgen Biopharma - Barchart.com

Jun 11, 2025
pulisher
Jun 11, 2025

Trend Tracker for (FHTX) - news.stocktradersdaily.com

Jun 11, 2025
pulisher
Jun 10, 2025

Millennium Management LLC Raises Stock Position in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World

Jun 10, 2025
pulisher
Jun 08, 2025

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Acquired by Wellington Management Group LLP - Defense World

Jun 08, 2025
pulisher
Jun 07, 2025

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives $12.13 Consensus Target Price from Analysts - Defense World

Jun 07, 2025
pulisher
Jun 03, 2025

BNP Paribas Financial Markets Makes New $61,000 Investment in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World

Jun 03, 2025
pulisher
May 29, 2025

Trading (FHTX) With Integrated Risk Controls - news.stocktradersdaily.com

May 29, 2025
pulisher
May 29, 2025

Northern Trust Corp Purchases 2,873 Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World

May 29, 2025
pulisher
May 26, 2025

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Position Increased by D. E. Shaw & Co. Inc. - Defense World

May 26, 2025
pulisher
May 26, 2025

Lazard Asset Management LLC Acquires New Shares in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World

May 26, 2025
pulisher
May 22, 2025

Foghorn Therapeutics Inc. to Participate in Major Upcoming Healthcare Conferences in 2025 - Nasdaq

May 22, 2025
pulisher
May 22, 2025

Foghorn Therapeutics to Participate in Four Upcoming Investor Conferences - GlobeNewswire

May 22, 2025
pulisher
May 20, 2025

10,895 Shares in Foghorn Therapeutics Inc. (NASDAQ:FHTX) Acquired by Cubist Systematic Strategies LLC - Defense World

May 20, 2025
pulisher
May 19, 2025

(FHTX) Trading Report - news.stocktradersdaily.com

May 19, 2025
pulisher
May 19, 2025

Q2 EPS Estimate for Foghorn Therapeutics Cut by Analyst - Defense World

May 19, 2025
pulisher
May 19, 2025

Wedbush Expects Weaker Earnings for Foghorn Therapeutics - Defense World

May 19, 2025
pulisher
May 17, 2025

JMP Securities Reiterates Market Outperform Rating for Foghorn Therapeutics (NASDAQ:FHTX) - Defense World

May 17, 2025
pulisher
May 15, 2025

Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates - MSN

May 15, 2025
pulisher
May 15, 2025

FHTX: JMP Securities Reiterates Market Outperform Rating for Fog - GuruFocus

May 15, 2025
pulisher
May 15, 2025

FHTX: JMP Securities Reiterates Market Outperform Rating for Foghorn Therapeutics | FHTX Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Foghorn Therapeutics Reports Q1 2025 Financial Results - TipRanks

May 15, 2025
pulisher
May 14, 2025

Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update - GlobeNewswire

May 14, 2025
pulisher
May 14, 2025

Foghorn Therapeutics: Pioneering Precision Medicine with Innovative Pharmacology and AI Integration - TipRanks

May 14, 2025
pulisher
May 14, 2025

Foghorn Therapeutics Inc. reports results for the quarter ended March 31Earnings Summary - TradingView

May 14, 2025
pulisher
May 14, 2025

FHTX Exceeds Revenue Expectations and Advances Pipeline Programs | FHTX Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Foghorn Therapeutics Advances FHD-909 Phase 1 Trial - TipRanks

May 14, 2025
pulisher
May 14, 2025

Foghorn Therapeutics Inc. SEC 10-Q Report - TradingView

May 14, 2025
pulisher
May 14, 2025

Foghorn Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

Foghorn Therapeutics Advances Cancer Drug Pipeline with Strong Financial Results: Phase 1 Trial Shows Promise - Stock Titan

May 14, 2025
pulisher
May 13, 2025

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Holdings Boosted by Wells Fargo & Company MN - Defense World

May 13, 2025
pulisher
May 13, 2025

Analysts Set Foghorn Therapeutics Inc. (NASDAQ:FHTX) PT at $12.13 - Defense World

May 13, 2025
pulisher
May 12, 2025

Ted Myles Joins Cellarity as Chief Executive Officer - Stock Titan

May 12, 2025
pulisher
May 12, 2025

Barclays PLC Increases Stock Position in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World

May 12, 2025
pulisher
May 08, 2025

(FHTX) Trading Advice - news.stocktradersdaily.com

May 08, 2025
pulisher
May 07, 2025

Renaissance Technologies LLC Acquires 22,500 Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World

May 07, 2025
pulisher
May 06, 2025

Foghorn Therapeutics’ SWOT analysis: chromatin pioneer’s stock faces clinical hurdles - Investing.com Nigeria

May 06, 2025
pulisher
May 05, 2025

Foghorn Therapeutics to Participate in the Citizens Life Sciences Conference - GlobeNewswire

May 05, 2025
pulisher
May 03, 2025

Foghorn Therapeutics (FHTX) Expected to Announce Quarterly Earnings on Monday - Defense World

May 03, 2025
pulisher
May 03, 2025

JPMorgan Chase & Co. Purchases 45,565 Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World

May 03, 2025
pulisher
May 01, 2025

Foghorn Therapeutics expands board with biotech veterans By Investing.com - Investing.com India

May 01, 2025
pulisher
May 01, 2025

Foghorn Therapeutics expands board with biotech veterans - Investing.com

May 01, 2025
pulisher
May 01, 2025

Foghorn Therapeutics Elects Neil Gallagher, M.D., Ph.D., and Stuart Duty to Board of Directors - Nasdaq

May 01, 2025
pulisher
May 01, 2025

Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors - GlobeNewswire

May 01, 2025
pulisher
Apr 29, 2025

Foghorn Therapeutics Presents New Preclinical Data on Selective - GuruFocus

Apr 29, 2025
pulisher
Apr 29, 2025

Geode Capital Management LLC Boosts Stake in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World

Apr 29, 2025
pulisher
Apr 28, 2025

FHTX Unveils Promising Preclinical Data at Cancer Research Confe - GuruFocus

Apr 28, 2025

Foghorn Therapeutics Inc Azioni (FHTX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Foghorn Therapeutics Inc Azioni (FHTX) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Costa Carlos
Chief People Officer
Sep 23 '24
Option Exercise
3.72
857
3,188
857
Costa Carlos
Chief People Officer
Sep 20 '24
Sale
10.04
35,756
358,990
0
Costa Carlos
Chief People Officer
Sep 23 '24
Sale
10.17
857
8,716
0
Costa Carlos
Chief People Officer
Sep 18 '24
Option Exercise
3.72
11,574
43,055
11,574
Costa Carlos
Chief People Officer
Sep 18 '24
Sale
10.05
11,574
116,319
0
Costa Carlos
Chief People Officer
Sep 17 '24
Option Exercise
3.72
10,272
38,212
10,272
Costa Carlos
Chief People Officer
Sep 16 '24
Option Exercise
3.72
400
1,488
400
Costa Carlos
Chief People Officer
Sep 17 '24
Sale
10.04
10,272
103,131
0
Costa Carlos
Chief People Officer
Sep 16 '24
Sale
10.00
400
4,000
0
$20.74
price up icon 0.39%
$35.88
price down icon 0.42%
$21.20
price down icon 0.38%
$97.62
price down icon 3.00%
$107.51
price up icon 0.98%
biotechnology ONC
$245.16
price up icon 1.28%
Capitalizzazione:     |  Volume (24 ore):